Skip to content

#Anxiety

  1. ClinicalTrials.gov: newly registered trials60

    NYU Langone registers trial of psilocybin-assisted psychotherapy for fear of cancer recurrence in early-stage breast cancer

    NYU Langone Health has registered a double-blind, parallel-design, placebo-controlled, two-centre randomised controlled trial of single-dose psilocybin-assisted psychotherapy in 100 outpatients with early-stage breast cancer. The trial is designed to evaluate efficacy and psychological mechanisms for fear of cancer recurrence (FCR), anxiety and depression distress and quality of life, comparing a single 25mg oral dose of psilocybin with a single 5mg oral dose as an active placebo, both delivered with a psychotherapy platform.

    Why it matters: The registry record sets out a two-centre design with an active placebo, so readers can see how the trial plans to separate psilocybin from expectancy in fear of cancer recurrence.

  1. STAT: psychedelics78

    Definium says LSD therapy DT120 eased anxiety in second late-stage trial

    Definium Therapeutics said its LSD therapy DT120 helped patients with anxiety in a second late-stage trial.

    Why it matters: The reported 5.1-point gap between DT120 and placebo mirrors the company's first late-stage anxiety study, so the pending regulatory filing will test whether that effect size holds up in a review.

You have reached the end